Loading...
•
Jun 29, 2024
Bioventus Q2 2024 Earnings Report
Reported strong financial results in the second quarter, with double-digit organic growth and increased profitability.
Key Takeaways
Bioventus reported a 10.3% increase in worldwide revenue, reaching $151.2 million. Organic revenue growth was 13.9%, driven by Pain Treatments and Surgical Solutions. The company raised its full-year 2024 financial guidance, expecting net sales of $557 million to $567 million and adjusted EBITDA of $104 million to $107 million.
Worldwide revenue increased by 10.3% to $151.2 million.
Organic revenue advanced by 13.9%, driven by double-digit growth in Pain Treatments and Surgical Solutions.
Adjusted EBITDA from continuing operations advanced 22.4% to $34.5 million.
The company raised financial guidance for full-year 2024.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Bioventus is raising financial guidance for the full-year 2024.
Positive Outlook
- Net sales of $557 million to $567 million
- Adjusted EBITDA of $104 million to $107 million
- Non-GAAP EPS of $0.36 to $0.42
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...